Search
for

    Research 6 of 17

    1. NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders Journal of Medicinal Chemistry · 2025 · 45 citations
    2. Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One Journal of Medicinal Chemistry · 2022 · 10 citations
    3. Nanoliposomal Co-Delivery of AR-PROTAC and NFKBIZ siRNA for Synergistic Therapy of Androgenetic Alopecia ACS Applied Bio Materials · 2026
    4. Evolving CRBN ligands enhance the drug-like properties of protein degraders Journal of Enzyme Inhibition and Medicinal Chemistry · 2026
    5. Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer Cancers · 2024
    6. Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment Cancer · 2025 · 3 citations
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →